
Tubulis
Tubulis develops antibody-drug conjugates (ADCs) for targeted cancer therapy.
$360M Series B+ ·
Led by Venrock Healthcare Capital Partners · Source: startupintros.com
Total raised: $573M across 4 sourced rounds
All 4 rounds ↓Acquired by GGilead Sciences on for $5B · Yahoo Finance.
Signals
About Tubulis
The company creates protein-drug conjugates with improved delivery, reduced toxicity, and enhanced therapeutic potential. Tubulis advances a pipeline of experimental drug candidates and collaborates with industry partners to expand oncology treatments. Its customers are partners and patients.
Tubulis | 2329 days on the record
Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | $360M | startupintros.com | ||
| Series B+ | $138M | endpts.com | ||
| Series B+ | $63M | bioworld.com | ||
| Series A | $12M | startupintros.com |
Timeline
- Acquired by
GGilead Sciences · $5B
Source: Yahoo Finance - Website created
Founders and team
- CHChristian Hackenberger scientific co-foundersource: tubulis.com
DS
Dominik Schumacher co-founderLinkedIn · source: tubulis.comJH
Jonas Helma-Smets CSO & Co-FounderBH
Björn Hock Chief Development OfficerIL
Ingo Lehrke CBO
Investors
AAndera Partnerslead investor
BBayern Kapital
BBioMedPartnerslead investor
CcoparionDDeep Track Capital
EEQT Life Scienceslead investor
EEvotec
FFidelity
FFrazier Life Sciences
FFund+
HHTGFlead investor
JJanus Henderson Investors
NNextech Investlead investor
OOCCIDENT
SSeventure Partners
VVenrock Healthcare Capital Partnerslead investor
WWellington Management
Companies like Tubulis
OOna Therapeutics$86.6M Series B+ · Oct 2026
AAdcendo$75M Series B+ · Apr 2026VVelosbioSeries B+ · Aug 2026
AAbTx$1.95M Seed · Sep 2026
PPhrontline Biopharma$40M Series A · Nov 2026
PPanTargPre Seed · Sep 2026
Other companies backed by Venrock Healthcare Capital Partners
CCellCentric$220M Series B+ · May 2026
DDevoted Health$366M Series B+ · Mar 2026
AAngitia Bio$130M Series B+ · Feb 2026
Venrock Healthcare Capital Partners portfolio →
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/tubulis-gmbh (get a free API key).